<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561053</url>
  </required_header>
  <id_info>
    <org_study_id>IG1002</org_study_id>
    <nct_id>NCT01561053</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease</brief_title>
  <acronym>AMBAR</acronym>
  <official_title>A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grifols Biologicals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grifols Biologicals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral
      and global domains based on the different applicable psychometric batteries and scales.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A clinical trial comprised of 350 subjects with probable mild to moderate Alzheimer's Disease
      (AD) will be conducted primarily to determine whether plasmapheresis with infusion of human
      albumin combined with Intravenous immunoglobulin (IVIG) is able to modify patient's
      cognitive, functional, behavioral and global domains. There will be 3 treatment groups and
      one control group. The subjects will be randomized in a 1:1:1:1 proportion.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive scores (as a change from baseline measurement), measured by ADAS-Cog (Cognitive subscale of the Alzheimer's Disease Assessment Scale) and ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living).</measure>
    <time_frame>14 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive, functional and neuropsychiatric scores and overall development as measured by MMSE, NPS battery, ADCS-ADL, NPICDR-Sb, ADCS-CGIC, CSDD, C-SSRS and QoL-AD, RUD-lite.</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of AB1-40 and AB1-42, T-tau and P-tau in CSF</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of AB1-40 and AB1-42 in plasma</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the structural changes in volume of the hippocampus, posterior cingulate area, and other associated areas based on neuroimaging study with magnetic resonance imaging (MRI) variation versus baseline.</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in FDG-PET patterns (flurodeoxyglucose-PET)</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Treatment group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmaexchange with 20% albumin and Immune Globulin (IGIV) high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmaexchange with 20% albumin and Immune Globulin (IGIV) low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmaexchange with 20% albumin (low dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (sham) group - Simulated procedure</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment with previously prescribed medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Human albumin 20%</description>
    <arm_group_label>Treatment group 1</arm_group_label>
    <arm_group_label>Treatment group 2</arm_group_label>
    <arm_group_label>Treatment group 3</arm_group_label>
    <other_name>Albutein 20%</other_name>
    <other_name>Human Albumin Grifols 20%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune globulin</intervention_name>
    <description>Intravenous (human) immune globulin 5%</description>
    <arm_group_label>Treatment group 1</arm_group_label>
    <arm_group_label>Treatment group 2</arm_group_label>
    <arm_group_label>Treatment group 3</arm_group_label>
    <other_name>Flebogamma DIF 5%</other_name>
    <other_name>flebogammadif 5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Males or females between 55-85 years of age at the time of signing of the informed
             consent document.

          2. A diagnosis of Alzheimer's disease (NINCDS-ADRDA criterion), and MMSE score between
             &gt;/=18 and &lt;/=26.

          3. Current stable treatment with AChEIs and/or memantine for the previous three months.

          4. The patient and a close relative or the legal representative must read the patient
             information sheet, agree to participation in the trial, and then sign the informed
             consent document (the patient personally and the close relative/legal representative).

          5. The patient must be able to follow the study protocol, receive the treatment in the
             established time period, and continue during the follow-up interval.

          6. A brain CAT or MRI study obtained in the 12 months prior to recruitment, showing the
             absence of cerebrovascular disease, should be available. Nevertheless, it is possible
             to use the MRI obtained during the screening period to rule out any cerebral vascular
             disease.

          7. A stable care taker must be available, and must attend the patient study visits.

        Main Exclusion Criteria:

          1. Any contraindication for plasma exchange due to behavioral disorders or abnormal
             coagulation parameters, such as for example:

               -  Hypocalcemia (Ca++ &lt; 8.7 mg/dL)

               -  Thrombocytopenia (&lt;100,000/µL)

               -  Fibrinogen &lt;1.5 g/L)

               -  Prothrombin time (Quick) p&lt;60% versus control (INR &gt;1.5)

               -  Beta-blocker treatment and bradycardia &lt;60/min)

               -  Treatment with angiotension-converting enzyme inhibitors (ACEIs) (increased risk
                  of allergic reactions)

          2. Hemoglobin &lt; 10 mg/dL

          3. Difficult venous access precluding plasma exchange.

          4. A history of frequent adverse reactions (serious or otherwise) to blood products.

          5. Hypersensitivity to albumin or allergies to any of the components of Albutein® 5%.

          6. History of immunoglobulin A (IgA) deficiency.

          7. Known allergies to Flebogamma® DIF components such as sorbitol.

          8. History of thromboembolic complications of intravenous immunoglobulins.

          9. Plasma creatinine &gt; 2 mg/dl.

         10. Uncontrolled high blood pressure (systolic blood pressure of 160 mmHg or higher and/or
             diastolic blood pressure of 100 mmHg or higher despite treatment during the last 3
             months).

         11. Liver cirrhosis or any liver problem with GPT &gt; 2.5 x ULN, or bilirubin &gt; 2 mg/dL.

         12. Heart diseases, as evidenced by myocardial infarction, severe or unstable angina, or
             heart failure (New York Association Class II, III or IV) in the past 12 months.

         13. Participation in other clinical trials, or the receiption of any other investigational
             drug in the three months prior to the start of the study.

         14. Any condition complicating adherence to the study protocol (illness with less than one
             year of expected survival, known drug or alcohol abuse, etc.).

         15. Pregnant or nursing women or women not using effective contraceptive methods for at
             least one month after plasma exchange.

         16. Fewer than six years of education (exclusion criteria under medical criterion).

         17. Fewer than three months with stable treatment for behavioral disorders or insomnia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merce Boada Rovira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació ACE. Barcelona. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Páez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Grifols, S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Núñez, BSc</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Grifols, S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research, Inc</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradenton Research Center, Inc.</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Laboratories</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galiz Research, LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L&amp;L Research Choices, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Biomedical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Dade Medical Research Institute, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaSeek LLC (DMI Research)</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTR Medical Group</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31419</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Atlantic Geriatric/ARC</name>
      <address>
        <city>Manchester Township</city>
        <state>New Jersey</state>
        <zip>08759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The NeuroCognitive Institute</name>
      <address>
        <city>Mount Arlington</city>
        <state>New Jersey</state>
        <zip>08756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Healthcare</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Neurology Clinic</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Vinalopó</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03293</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Torrevieja</name>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Catalunya</name>
      <address>
        <city>San Cugat del Valles</city>
        <state>Barcelona</state>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ntra. Sra. de la Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Canary Islands</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Funcació ACE</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario De Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parc Hospitalari Marti i Julia</name>
      <address>
        <city>Girona</city>
        <zip>17190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa María</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Montecanal</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>AB peptide</keyword>
  <keyword>Albumin</keyword>
  <keyword>Intravenous immune globulin</keyword>
  <keyword>IGIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

